

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the annual general meeting of CF PharmTech, Inc. (the “**Company**”) will be held at No. 16, Hucundang Road, Xiangcheng Economic Development District, Suzhou, Jiangsu, PRC, on Friday, June 26, 2026 at 10:00 a.m. for the following purposes:

ORDINARY RESOLUTIONS

1. To consider and approve the audited consolidated financial statements of the Company for the year ended December 31, 2025.
2. To consider and approve the annual report of the Company for the year ended December 31, 2025.
3. To consider and approve the:
 - 3.1 election of Dr. LIANG Bill Wenqing as executive Director for the Fourth Session of the Board;
 - 3.2 election of Dr. LI LI BOVET as executive Director for the Fourth Session of the Board;
 - 3.3 election of Dr. LI Qi as executive Director for the Fourth Session of the Board;
 - 3.4 election of Ms. ZHU Yuyu as executive Director for the Fourth Session of the Board;
 - 3.5 election of Ms. ZHANG Jingjing as executive Director for the Fourth Session of the Board;
 - 3.6 election of Mr. CAI Lei as non-executive Director for the Fourth Session of the Board;

- 3.7 election of Dr. YI Hua as non-executive Director for the Fourth Session of the Board;
 - 3.8 election of Dr. JIN Jian as independent non-executive Director for the Fourth Session of the Board;
 - 3.9 election of Ms. WANG Lijuan as independent non-executive Director for the Fourth Session of the Board;
 - 3.10 election of Mr. WEI Shirong as independent non-executive Director for the Fourth Session of the Board; and
 - 3.11 election of Mr. IP Wang Hoi as independent non-executive Director for the Fourth Session of the Board.
4. To consider and approve the:
 - 4.1 election of Ms. CHENG Xiangfeng as Supervisor for the Fourth Session of the Supervisory Committee;
 - 4.2 election of Ms. KUAI Jingjing as Supervisor for the Fourth Session of the Supervisory Committee; and
 - 4.3 election of Mr. ZHENG Yao as Supervisor for the Fourth Session of the Supervisory Committee.
 5. To consider and approve the re-appointment of Ernst & Young as the auditor of the Company for a term until the conclusion of the next annual general meeting of the Company and to authorise the Board to determine its remuneration.
 6. To consider and approve the proposed amendments to the 2025 H Share Award Trust Scheme (the “**H Share Award Scheme**”) to, among others, expand the scope of eligible participants thereunder to include service providers, the details of which are set out in Appendix IV to the circular of the Company dated June 2, 2026, and to authorize the Board and/or its delegatee to implement the amended H Share Award Scheme.

SPECIAL RESOLUTIONS

7. To consider and approve the proposal regarding the grant of a general mandate to the Board to allot, issue and/or deal with (including any sale or transfer of treasury shares, if permitted under the Listing Rules) additional H shares of the Company not exceeding 20% of the total number of H shares of the Company in issue (excluding treasury shares), and to authorise the Board to make such amendments as it deems

appropriate to the provisions of the articles of association of the Company, so as to reflect the new capital structure upon additional allotment and issuance of shares pursuant to such mandate. Details of the resolution are set out in the circular of the Company.

8. To consider and, if thought fit, to approve the following general mandate for the Board and the persons authorised by the Board to repurchase H Shares of the Company:

(a) the Board be granted a general mandate, by reference to market conditions and in accordance with needs of the Company, to repurchase shares of the Company not exceeding 10% of the total number of H shares of the Company in issue (excluding treasury shares) at the time when this resolution is passed at the Annual General Meeting.

(b) the Board be authorised to (including but not limited to the following):

(i) formulate and implement the repurchase plan, including but not limited to determining the time of repurchase, period of repurchase, repurchase price and number of shares to repurchase, etc.;

(ii) notify creditors and issue announcements pursuant to the requirements of the laws and regulations such as PRC Company Law and the articles of association of the Company;

(iii) open overseas share accounts and money accounts and to carry out related change of foreign exchange registration procedures;

(iv) carry out relevant procedures or filing procedures (if any) pursuant to the applicable laws, regulations and rules; and

(v) carry out cancellation procedures for bought back shares not held by the Company as treasury shares, make corresponding amendments to the articles of association of the Company relating to, among others, share capital and shareholdings, and carry out modification registrations and make filings.

(c) Authorisation period

The period of above general mandate shall not exceed the relevant period (the “**Relevant Period**”). The Relevant Period commences from the day when the authority conferred by this special resolution is approved by a special resolution of shareholders at the Annual General Meeting and ends at the earlier of:

- (i) the conclusion of the next annual general meeting of the Company following the date of passing of this resolution;
- (ii) the expiration of a period of twelve months following the passing of this special resolution at the Annual General Meeting; or
- (iii) the date on which the authority conferred by this resolution is revoked or varied by a special resolution of shareholders at a general meeting.

By order of the Board

CF PharmTech, Inc.

長風藥業股份有限公司

Dr. LIANG Bill Wenqing

Chairperson, Executive Director and Chief Executive Officer

Hong Kong, June 2, 2026

*Registered office and Headquarters
in the PRC:*

No. 16, Hucundang Road
Xiangcheng Economic
Development District
Suzhou Jiangsu
PRC

*Principal place of business
in Hong Kong:*

31/F., Tower Two
Times Square
1 Matheson Street
Causeway Bay
Hong Kong

Notes:

1. All resolutions at the Annual General Meeting will be taken by poll pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The results of the poll will be published on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.cfpharmtech.com) in accordance with the Listing Rules.
2. All shareholders of the Company are eligible for attending the Annual General Meeting. Any shareholder of the Company entitled to attend and vote at the Annual General Meeting convened by the above notice is entitled to appoint a proxy or more than one proxy to attend the Annual General Meeting and vote instead of him/her. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant proxy form. Every shareholder of the Company present in person or by proxy shall be entitled to one vote for each share held by him/her.
3. In order to be valid, the proxy form together with the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy thereof, must be completed and returned to the Company’s H share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong not less than 24 hours before the time appointed for the Annual General Meeting or any adjournment thereof (as the case may be). Completion and return of the proxy form will not preclude a shareholder of the Company from attending and voting at the Annual General Meeting or any adjourned meeting thereof should he/she so wish.
4. For determining the entitlement to attend and vote at the Annual General Meeting, the register of members of the Company will be closed from Tuesday, June 23, 2026 to Friday, June 26, 2026, both days inclusive, during which period no transfer of shares will be registered. The record date will be Friday, June 26, 2026. In order to qualify for attending and voting at the Annual General Meeting, holders of shares of the Company whose

transfer documents have not been registered are required to submit the share certificates together with the properly completed share transfer forms to the Company's H share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Monday, June 22, 2026.

5. The instrument appointing the proxy must be in writing and signed by the appointor or his/her attorney duly authorised in writing, or if the appointer is a legal person, either under a legal person's seal or signed by its director or an attorney duly authorised in writing.
6. The Annual General Meeting (or any adjournment thereof) is expected to take no more than half a day. Shareholders of the Company or their proxies attending the Annual General Meeting (or any adjournment thereof) shall bear their own travelling and accommodation expenses.

As at the date of this notice, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.